PD-1/CTLA-4 Blockade Inhibits Epstein-Barr Virus-Induced Lymphoma Growth in a Cord Blood Humanized-Mouse Model

PLoS Pathogens

Volumn 12, Issue 5, 2016, Pages

  Ma, Shi Dong ^a   Xu, Xuequn ^a   Jones, Richard ^b   Delecluse, Henri Jacques ^c,d   Zumwalde, Nicholas A ^a   Sharma, Akshat ^a   Gumperz, Jenny E ^a   Kenney, Shannon C ^a  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b UNIVERSITY OF TEXAS   (United States)

^c GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^d Institut National de la Sante et de la Recherche Medicale U701   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CD19 ANTIBODY; CD20 ANTIBODY; CD34 ANTIBODY; CD45 ANTIGEN; CELL MARKER; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; GAMMA INTERFERON; IPILIMUMAB; OKT 3; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 LIGAND 2; PROGRAMMED DEATH 1 RECEPTOR; T LYMPHOCYTE RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CANCER GROWTH; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL INFILTRATION; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; ENZYME LINKED IMMUNOSORBENT ASSAY; EPSTEIN BARR VIRUS; EPSTEIN BARR VIRUS INFECTION; FLOW CYTOMETRY; GENE EXPRESSION; HUMAN; IMMUNOHISTOCHEMISTRY; LARGE CELL LYMPHOMA; LYMPHOMA; MOUSE; MOUSE MODEL; MUTAGENESIS; NOD SCID GAMMA MOUSE; NONHUMAN; T LYMPHOCYTE ACTIVATION; TUMOR MICROENVIRONMENT; UMBILICAL CORD BLOOD; VIRUS GENE; ANIMAL; B CELL LYMPHOMA; COMPLICATION; DISEASE MODEL; FETUS BLOOD; IMMUNOLOGY; METABOLISM; NONOBESE DIABETIC MOUSE; SCID MOUSE; VIROLOGY;

ANIMALS; CTLA-4 ANTIGEN; DISEASE MODELS, ANIMAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPSTEIN-BARR VIRUS INFECTIONS; FETAL BLOOD; FLOW CYTOMETRY; HERPESVIRUS 4, HUMAN; HUMANS; LYMPHOMA, B-CELL; MICE; MICE, INBRED NOD; MICE, SCID; PROGRAMMED CELL DEATH 1 RECEPTOR;

EID: 84973327169     PISSN: 15537366     EISSN: 15537374     Source Type: Journal    
DOI: 10.1371/journal.ppat.1005642     Document Type: Article

References (68)

1. Vereide D, Sugden B, Insights into the evolution of lymphomas induced by Epstein-Barr virus. Advances in cancer research. 2010;108:1–19. doi: 10.1016/B978-0-12-380888-2.00001-721034964
2. Vereide DT, Sugden B, Lymphomas differ in their dependence on Epstein-Barr virus. Blood. 2011;117(6):1977–85. doi: 10.1182/blood-2010-05-28579121088132
3. Hatton OL, Harris-Arnold A, Schaffert S, Krams SM, Martinez OM, The interplay between Epstein-Barr virus and B lymphocytes: implications for infection, immunity, and disease. Immunol Res. 2014;58(2–3):268–76. doi: 10.1007/s12026-014-8496-124619311
4. Houldcroft CJ, Kellam P, Host genetics of Epstein-Barr virus infection, latency and disease. Rev Med Virol. 2015;25(2):71–84. doi: 10.1002/rmv.181625430668
5. Manzo T, Heslop HE, Rooney CM, Antigen-specific T cell therapies for cancer. Hum Mol Genet. 2015.
6. Adhikary D, Behrends U, Boerschmann H, Pfunder A, Burdach S, Moosmann A, et al. Immunodominance of lytic cycle antigens in Epstein-Barr virus-specific CD4+ T cell preparations for therapy. PLoS One. 2007;2(7):e583. 17611619
7. Merlo A, Turrini R, Dolcetti R, Martorelli D, Muraro E, Comoli P, et al. The interplay between Epstein-Barr virus and the immune system: a rationale for adoptive cell therapy of EBV-related disorders. Haematologica. 2010;95(10):1769–77. doi: 10.3324/haematol.2010.02368920421267
8. Agathanggelou A, Niedobitek G, Chen R, Nicholls J, Yin W, Young LS, Expression of immune regulatory molecules in Epstein-Barr virus-associated nasopharyngeal carcinomas with prominent lymphoid stroma. Evidence for a functional interaction between epithelial tumor cells and infiltrating lymphoid cells. Am J Pathol. 1995;147(4):1152–60. 7573360
9. Huang YT, Sheen TS, Chen CL, Lu J, Chang Y, Chen JY, et al. Profile of cytokine expression in nasopharyngeal carcinomas: a distinct expression of interleukin 1 in tumor and CD4+ T cells. Cancer Res. 1999;59(7):1599–605. 10197635
10. Lau KM, Cheng SH, Lo KW, Lee SA, Woo JK, van Hasselt CA, et al. Increase in circulating Foxp3+CD4+CD25(high) regulatory T cells in nasopharyngeal carcinoma patients. Br J Cancer. 2007;96(4):617–22. 17262084
11. Marshall NA, Vickers MA, Barker RN, Regulatory T cells secreting IL-10 dominate the immune response to EBV latent membrane protein 1. J Immunol. 2003;170(12):6183–9. 12794149
12. Alvaro T, Lejeune M, Salvado MT, Bosch R, Garcia JF, Jaen J, et al. Outcome in Hodgkin's lymphoma can be predicted from the presence of accompanying cytotoxic and regulatory T cells. Clin Cancer Res. 2005;11(4):1467–73. 15746048
13. Chen L, Han X, Anti-PD-1/PD-L1 therapy of human cancer: past, present, and future. J Clin Invest. 2015;125(9):3384–91. doi: 10.1172/JCI8001126325035
14. Alegre ML, Frauwirth KA, Thompson CB, T-cell regulation by CD28 and CTLA-4. Nat Rev Immunol. 2001;1(3):220–8. 11905831
15. McDermott DF, Atkins MB, PD-1 as a potential target in cancer therapy. Cancer Med. 2013;2(5):662–73. doi: 10.1002/cam4.10624403232
16. Boussiotis VA, Chatterjee P, Li L, Biochemical signaling of PD-1 on T cells and its functional implications. Cancer J. 2014;20(4):265–71. doi: 10.1097/PPO.000000000000005925098287
17. Pardoll DM, The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12(4):252–64. doi: 10.1038/nrc323922437870
18. Durand-Panteix S, Farhat M, Youlyouz-Marfak I, Rouaud P, Ouk-Martin C, David A, et al. B7-H1, which represses EBV-immortalized B cell killing by autologous T and NK cells, is oppositely regulated by c-Myc and EBV latency III program at both mRNA and secretory lysosome levels. J Immunol. 2012;189(1):181–90. doi: 10.4049/jimmunol.110227722661084
19. Rodriguez-Garcia M, Porichis F, de Jong OG, Levi K, Diefenbach TJ, Lifson JD, et al. Expression of PD-L1 and PD-L2 on human macrophages is up-regulated by HIV-1 and differentially modulated by IL-10. J Leukoc Biol. 2011;89(4):507–15. doi: 10.1189/jlb.061032721097698
20. Fang W, Zhang J, Hong S, Zhan J, Chen N, Qin T, et al. EBV-driven LMP1 and IFN-gamma up-regulate PD-L1 in nasopharyngeal carcinoma: Implications for oncotargeted therapy. Oncotarget. 2014;5(23):12189–202. 25361008
21. Green MR, Rodig S, Juszczynski P, Ouyang J, Sinha P, O'Donnell E, et al. Constitutive AP-1 activity and EBV infection induce PD-L1 in Hodgkin lymphomas and posttransplant lymphoproliferative disorders: implications for targeted therapy. Clin Cancer Res. 2012;18(6):1611–8. doi: 10.1158/1078-0432.CCR-11-194222271878
22. Romano A, Conticello C, Cavalli M, Vetro C, La Fauci A, Parrinello NL, et al. Immunological dysregulation in multiple myeloma microenvironment. Biomed Res Int. 2014;2014:198539. doi: 10.1155/2014/19853925013764
23. Quan L, Chen X, Liu A, Zhang Y, Guo X, Yan S, et al. PD-1 Blockade Can Restore Functions of T-Cells in Epstein-Barr Virus-Positive Diffuse Large B-Cell Lymphoma In Vitro. PLoS One. 2015;10(9):e0136476. doi: 10.1371/journal.pone.013647626361042
24. Larsen M, Sauce D, Deback C, Arnaud L, Mathian A, Miyara M, et al. Exhausted cytotoxic control of Epstein-Barr virus in human lupus. PLoS Pathog. 2011;7(10):e1002328. doi: 10.1371/journal.ppat.100232822028659
25. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363(8):711–23. doi: 10.1056/NEJMoa100346620525992
26. Sharma P, Wagner K, Wolchok JD, Allison JP, Novel cancer immunotherapy agents with survival benefit: recent successes and next steps. Nat Rev Cancer. 2011;11(11):805–12. doi: 10.1038/nrc315322020206
27. Ansell SM, Lesokhin AM, Borrello I, Halwani A, Scott EC, Gutierrez M, et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. N Engl J Med. 2015;372(4):311–9. doi: 10.1056/NEJMoa141108725482239
28. Kline J, Bishop MR, Update on checkpoint blockade therapy for lymphoma. J Immunother Cancer. 2015;3:33. doi: 10.1186/s40425-015-0079-826199729
29. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012;366(26):2443–54. doi: 10.1056/NEJMoa120069022658127
30. Hamid O, Robert C, Daud A, Hodi FS, Hwu WJ, Kefford R, et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med. 2013;369(2):134–44. doi: 10.1056/NEJMoa130513323724846
31. Topalian SL, Sznol M, McDermott DF, Kluger HM, Carvajal RD, Sharfman WH, et al. Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol. 2014;32(10):1020–30. doi: 10.1200/JCO.2013.53.010524590637
32. Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD, et al. Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. N Engl J Med. 2015;373(1):23–34. doi: 10.1056/NEJMoa150403026027431
33. Gajewski TF, Schreiber H, Fu YX, Innate and adaptive immune cells in the tumor microenvironment. Nat Immunol. 2013;14(10):1014–22. doi: 10.1038/ni.270324048123
34. Boussiotis VA, Somatic mutations and immunotherapy outcome with CTLA-4 blockade in melanoma. N Engl J Med. 2014;371(23):2230–2. doi: 10.1056/NEJMe141306125409261
35. Yadav M, Jhunjhunwala S, Phung QT, Lupardus P, Tanguay J, Bumbaca S, et al. Predicting immunogenic tumour mutations by combining mass spectrometry and exome sequencing. Nature. 2014;515(7528):572–6. doi: 10.1038/nature1400125428506
36. Ma SD, Xu X, Plowshay J, Ranheim EA, Burlingham WJ, Jensen JL, et al. LMP1-deficient Epstein-Barr virus mutant requires T cells for lymphomagenesis. J Clin Invest. 2015;125(1):304–15. doi: 10.1172/JCI7635725485679
37. Ma SD, Yu X, Mertz JE, Gumperz JE, Reinheim E, Zhou Y, et al. An Epstein-Barr Virus (EBV) mutant with enhanced BZLF1 expression causes lymphomas with abortive lytic EBV infection in a humanized mouse model. J Virol. 2012;86(15):7976–87. doi: 10.1128/JVI.00770-1222623780
38. Ma SD, Hegde S, Young KH, Sullivan R, Rajesh D, Zhou Y, et al. A new model of Epstein-Barr virus infection reveals an important role for early lytic viral protein expression in the development of lymphomas. J Virol. 2011;85(1):165–77. doi: 10.1128/JVI.01512-1020980506
39. Strowig T, Gurer C, Ploss A, Liu YF, Arrey F, Sashihara J, et al. Priming of protective T cell responses against virus-induced tumors in mice with human immune system components. J Exp Med. 2009;206(6):1423–34. doi: 10.1084/jem.2008172019487422
40. Yajima M, Imadome K, Nakagawa A, Watanabe S, Terashima K, Nakamura H, et al. T cell-mediated control of Epstein-Barr virus infection in humanized mice. J Infect Dis. 2009;200(10):1611–5. doi: 10.1086/64464419832115
41. Brinkman CC, Peske JD, Engelhard VH, Peripheral tissue homing receptor control of naive, effector, and memory CD8 T cell localization in lymphoid and non-lymphoid tissues. Front Immunol. 2013;4:241. doi: 10.3389/fimmu.2013.0024123966998
42. Peske JD, Woods AB, Engelhard VH, Control of CD8 T-Cell Infiltration into Tumors by Vasculature and Microenvironment. Advances in cancer research. 2015;128:263–307. doi: 10.1016/bs.acr.2015.05.00126216636
43. Peske JD, Thompson ED, Gemta L, Baylis RA, Fu YX, Engelhard VH, Effector lymphocyte-induced lymph node-like vasculature enables naive T-cell entry into tumours and enhanced anti-tumour immunity. Nat Commun. 2015;6:7114. doi: 10.1038/ncomms811425968334
44. Pan M, Winslow MM, Chen L, Kuo A, Felsher D, Crabtree GR, Enhanced NFATc1 nuclear occupancy causes T cell activation independent of CD28 costimulation. J Immunol. 2007;178(7):4315–21. 17371988
45. Uchihara JN, Krensky AM, Matsuda T, Kawakami H, Okudaira T, Masuda M, et al. Transactivation of the CCL5/RANTES gene by Epstein-Barr virus latent membrane protein 1. Int J Cancer. 2005;114(5):747–55. 15609310
46. Katz BZ, Andiman WA, Eastman R, Martin K, Miller G, Infection with two genotypes of Epstein-Barr virus in an infant with AIDS and lymphoma of the central nervous system. J Infect Dis. 1986;153(3):601–4. 3005427
47. Carbone A, Cesarman E, Spina M, Gloghini A, Schulz TF, HIV-associated lymphomas and gamma-herpesviruses. Blood. 2009;113(6):1213–24. doi: 10.1182/blood-2008-09-18031518955561
48. Martis N, Mounier N, Hodgkin lymphoma in patients with HIV infection: a review. Curr Hematol Malig Rep. 2012;7(3):228–34. doi: 10.1007/s11899-012-0125-222547166
49. Gloghini A, Dolcetti R, Carbone A, Lymphomas occurring specifically in HIV-infected patients: from pathogenesis to pathology. Semin Cancer Biol. 2013;23(6):457–67. doi: 10.1016/j.semcancer.2013.08.00423999127
50. Papadopoulos EB, Ladanyi M, Emanuel D, Mackinnon S, Boulad F, Carabasi MH, et al. Infusions of donor leukocytes to treat Epstein-Barr virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation. N Engl J Med. 1994;330(17):1185–91. 8093146
51. Shapiro RS, McClain K, Frizzera G, Gajl-Peczalska KJ, Kersey JH, Blazar BR, et al. Epstein-Barr virus associated B cell lymphoproliferative disorders following bone marrow transplantation. Blood. 1988;71(5):1234–43. 2833957
52. Chattopadhyay PK, Chelimo K, Embury PB, Mulama DH, Sumba PO, Gostick E, et al. Holoendemic malaria exposure is associated with altered Epstein-Barr virus-specific CD8(+) T-cell differentiation. J Virol. 2013;87(3):1779–88. doi: 10.1128/JVI.02158-1223175378
53. Piriou E, Asito AS, Sumba PO, Fiore N, Middeldorp JM, Moormann AM, et al. Early age at time of primary Epstein-Barr virus infection results in poorly controlled viral infection in infants from Western Kenya: clues to the etiology of endemic Burkitt lymphoma. J Infect Dis. 2012;205(6):906–13. doi: 10.1093/infdis/jir87222301635
54. Asano N, Yamamoto K, Tamaru J, Oyama T, Ishida F, Ohshima K, et al. Age-related Epstein-Barr virus (EBV)-associated B-cell lymphoproliferative disorders: comparison with EBV-positive classic Hodgkin lymphoma in elderly patients. Blood. 2009;113(12):2629–36. doi: 10.1182/blood-2008-06-16480619075188
55. Deacon EM, Pallesen G, Niedobitek G, Crocker J, Brooks L, Rickinson AB, et al. Epstein-Barr virus and Hodgkin's disease: transcriptional analysis of virus latency in the malignant cells. J Exp Med. 1993;177(2):339–49. 8381153
56. Young LS, Dawson CW, Clark D, Rupani H, Busson P, Tursz T, et al. Epstein-Barr virus gene expression in nasopharyngeal carcinoma. J Gen Virol. 1988;69 (Pt 5):1051–65. 2836550
57. Gottschalk S, Edwards OL, Sili U, Huls MH, Goltsova T, Davis AR, et al. Generating CTLs against the subdominant Epstein-Barr virus LMP1 antigen for the adoptive immunotherapy of EBV-associated malignancies. Blood. 2003;101(5):1905–12. 12411306
58. Haigh TA, Lin X, Jia H, Hui EP, Chan AT, Rickinson AB, et al. EBV latent membrane proteins (LMPs) 1 and 2 as immunotherapeutic targets: LMP-specific CD4+ cytotoxic T cell recognition of EBV-transformed B cell lines. J Immunol. 2008;180(3):1643–54. 18209060
59. Le Clorennec C, Ouk TS, Youlyouz-Marfak I, Panteix S, Martin CC, Rastelli J, et al. Molecular basis of cytotoxicity of Epstein-Barr virus (EBV) latent membrane protein 1 (LMP1) in EBV latency III B cells: LMP1 induces type II ligand-independent autoactivation of CD95/Fas with caspase 8-mediated apoptosis. J Virol. 2008;82(13):6721–33. doi: 10.1128/JVI.02250-0718448526
60. Brooks JM, Lee SP, Leese AM, Thomas WA, Rowe M, Rickinson AB, Cyclical expression of EBV latent membrane protein 1 in EBV-transformed B cells underpins heterogeneity of epitope presentation and CD8+ T cell recognition. J Immunol. 2009;182(4):1919–28. doi: 10.4049/jimmunol.071360719201845
61. Cancer Genome Atlas Research NComprehensive molecular characterization of gastric adenocarcinoma. Nature. 2014;513(7517):202–9. doi: 10.1038/nature1348025079317
62. Hamid O, Schmidt H, Nissan A, Ridolfi L, Aamdal S, Hansson J, et al. A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma. J Transl Med. 2011;9:204. doi: 10.1186/1479-5876-9-20422123319
63. White RE, Ramer PC, Naresh KN, Meixlsperger S, Pinaud L, Rooney C, et al. EBNA3B-deficient EBV promotes B cell lymphomagenesis in humanized mice and is found in human tumors. J Clin Invest. 2012;122(4):1487–502. doi: 10.1172/JCI5809222406538
64. Levitskaya J, Coram M, Levitsky V, Imreh S, Steigerwald-Mullen PM, Klein G, et al. Inhibition of antigen processing by the internal repeat region of the Epstein-Barr virus nuclear antigen-1. Nature. 1995;375(6533):685–8. 7540727
65. Yin Y, Manoury B, Fahraeus R, Self-inhibition of synthesis and antigen presentation by Epstein-Barr virus-encoded EBNA1. Science. 2003;301(5638):1371–4. 12958359
66. Kyi C, Postow MA, Checkpoint blocking antibodies in cancer immunotherapy. FEBS Lett. 2014;588(2):368–76. doi: 10.1016/j.febslet.2013.10.01524161671
67. Tsai MH, Raykova A, Klinke O, Bernhardt K, Gartner K, Leung CS, et al. Spontaneous lytic replication and epitheliotropism define an Epstein-Barr virus strain found in carcinomas. Cell Rep. 2013;5(2):458–70. doi: 10.1016/j.celrep.2013.09.01224120866
68. Dirmeier U, Neuhierl B, Kilger E, Reisbach G, Sandberg ML, Hammerschmidt W, Latent membrane protein 1 is critical for efficient growth transformation of human B cells by epstein-barr virus. Cancer Res. 2003;63(11):2982–9. 12782607